Prelude Therapeutics Incorporated logo

Prelude Therapeutics IncorporatedNASDAQ: PRLD

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

25 September 2020

Next earnings report:

14 February 2025

Last dividends:

N/A

Next dividends:

N/A
$52.93 M
-92%vs. 3y high
35%vs. sector
-vs. 3y high
-vs. sector
-84%vs. 3y high
22%vs. sector
-54%vs. 3y high
84%vs. sector

Price

after hours | Wed, 20 Nov 2024 21:02:23 GMT
$0.96-$0.03(-2.93%)

Dividend

No data over the past 3 years
$3.00 M-$32.27 M

Analysts recommendations

Institutional Ownership

PRLD Latest News

Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD)
zacks.com11 November 2024 Sentiment: POSITIVE

Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
globenewswire.com09 September 2024 Sentiment: POSITIVE

PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST)

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
globenewswire.com12 August 2024 Sentiment: POSITIVE

Interim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in September

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
globenewswire.com03 June 2024 Sentiment: NEUTRAL

WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.

All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy
Zacks Investment Research04 October 2023 Sentiment: POSITIVE

Prelude Therapeutics Incorporated (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
GlobeNewsWire11 April 2023 Sentiment: POSITIVE

Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline

What type of business is Prelude Therapeutics Incorporated?

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

What sector is Prelude Therapeutics Incorporated in?

Prelude Therapeutics Incorporated is in the Healthcare sector

What industry is Prelude Therapeutics Incorporated in?

Prelude Therapeutics Incorporated is in the Biotechnology industry

What country is Prelude Therapeutics Incorporated from?

Prelude Therapeutics Incorporated is headquartered in United States

When did Prelude Therapeutics Incorporated go public?

Prelude Therapeutics Incorporated initial public offering (IPO) was on 25 September 2020

What is Prelude Therapeutics Incorporated website?

https://preludetx.com

Is Prelude Therapeutics Incorporated in the S&P 500?

No, Prelude Therapeutics Incorporated is not included in the S&P 500 index

Is Prelude Therapeutics Incorporated in the NASDAQ 100?

No, Prelude Therapeutics Incorporated is not included in the NASDAQ 100 index

Is Prelude Therapeutics Incorporated in the Dow Jones?

No, Prelude Therapeutics Incorporated is not included in the Dow Jones index

When was Prelude Therapeutics Incorporated the previous earnings report?

No data

When does Prelude Therapeutics Incorporated earnings report?

The next expected earnings date for Prelude Therapeutics Incorporated is 14 February 2025